Safety and Efficacy of Current DAA Regimens in Kidney and Liver Transplant Recipients with Hepatitis C: Results from the HCV-TARGET Study. Saxena V, Khungar V, Verna EC, Levitsky J, Brown RS, Hassan MA, Sulkowski MS, O'Leary JG, Koraishy F, Galati…

NEW YORK (Reuters Health) - Healthcare workers exposed to body fluids contaminated with hepatitis C virus (HCV) or the human immunodeficiency virus (HIV) face very low rates of seroconversion, researchers report. (Medscape, 09.05.2017) http://www.m…

Seroconversion rates among health care workers exposed to hepatitis C virus-contaminated body fluids: The University of Pittsburgh 13-year experience. Egro FM, Nwaiwu CA, Smith S, Harper JD, Spiess AM. Am J Infect Control. 2017 Apr 24. pii: S0196-…

Sofosbuvir-velpatasvir with ribavirin for 24 weeks in HCV patients previously treated with a direct-acting antiviral regimen. Gane EJ, Shiffman ML, Etzkorn K, Morelli G, Stedman C, Davis MN, Hinestrosa F, Dvory-Sobol H, Huang KC, Osinusi A, McNally…

State HCV Incidence and Policies Related to HCV Preventive and Treatment Services for Persons Who Inject Drugs — United States, 2015–2016 Campbell CA, Canary L, Smith N, Teshale E, Ryerson AB, Ward JW. MMWR Morb Mortal Wkly Rep. 2017 M…

AMSTERDAM — Almost all patients with hepatitis C who took legally imported generic versions of direct-acting antiviral agents achieved a sustained virologic response at 4 weeks, according to a new study. "Treatment with generics works,"…